We are live on ! Find out more
LPCN icon

Lipocine
LPCN

45 hedge funds and large institutions have $16.6M invested in Lipocine in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,400% more call options, than puts

Call options by funds: $65K | Put options by funds: $1K

298% more capital invested

Capital invested by funds: $4.16M → $16.6M (+$12.4M)

0.03% less ownership

Funds ownership: 0.7% → 0.67% (-0.03%)

8% less funds holding

Funds holding: 49 → 45 (-4)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
45
Holders Change
-4
Holders Change %
-8.16%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
9
Reduced
11
Closed
10
Calls
$65K
Puts
$1K
Net Calls
+$64K
Net Calls Change
-$398K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.7K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$36.1K
3
CA
Carson Advisory
Georgia
+$23.6K
4
EWA
EP Wealth Advisors
California
+$18.3K
5
Jane Street
Jane Street
New York
+$11.1K

Top Sellers

1
WE
Wealth Effects
Massachusetts
-$192K
2
Mercer Global Advisors
Mercer Global Advisors
Colorado
-$63K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$33.2K
4
B
Bailard
California
-$31.9K
5
Two Sigma Investments
Two Sigma Investments
New York
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
AWA
26
Aaron Wealth Advisors
Illinois
$11.4K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$9K +$3.28K +425 +37%
UBS Group
28
UBS Group
Switzerland
$7.99K +$6.2K +803 +119%
Morgan Stanley
29
Morgan Stanley
New York
$7.47K – – –
MSAM
30
Moloney Securities Asset Management
Missouri
$7.16K – – –
VF
31
Virtu Financial
New York
$7K +$9.31K +1,205 New
CWM
32
Cornerstone Wealth Management
Missouri
$5.09K +$7.27K +941 New
AAM
33
Azzad Asset Management
Virginia
$4.77K +$6.81K +882 New
KPWS
34
Kestra Private Wealth Services
Texas
$4.6K – – –
SCA
35
Snowden Capital Advisors
New York
$4K – – –
CG
36
Cutler Group
California
$4K – – –
Creative Planning
37
Creative Planning
Kansas
$3.18K – – –
Acadian Asset Management
38
Acadian Asset Management
Massachusetts
$3K -$33.2K -4,298 -86%
CSC
39
Caldwell Sutter Capital
California
$2.54K +$3.64K +471 New
JP Morgan Chase
40
JP Morgan Chase
New York
$1K – – –
Group One Trading
41
Group One Trading
Illinois
$651 +$927 +120 New
Osaic Holdings
42
Osaic Holdings
Arizona
$365 – – –
Bank of America
43
Bank of America
North Carolina
$318 -$85 -11 -16%
Wells Fargo
44
Wells Fargo
California
$195 +$8 +1 +3%
NC
45
NewSquare Capital
Pennsylvania
$64 – – –
Mercer Global Advisors
46
Mercer Global Advisors
Colorado
– -$63K -9,359 Closed
B
47
Bailard
California
– -$31.9K -4,880 Closed
MFG
48
Merit Financial Group
Georgia
– -$11.9K -1,759 Closed
PMFA
49
Plante Moran Financial Advisors
Michigan
– -$7.72K -1,000 Closed
TSS
50
Two Sigma Securities
New York
– -$6.68K -988 Closed
1
2
3

LPCN Hedge Fund Activity: Q1 2023 in Review

45 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2023, worth a combined $16.6M — up 298% from $4.16M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of LPCN and 6 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Millennium Management, adding an estimated $55.7K. The largest seller was Wealth Effects, cutting an estimated $192K.

  • 45 institutional investors held Lipocine (LPCN) as of Q1 2023, down from 49 in Q4 2022.
  • Funds reported $16.6M of Lipocine stock for Q1 2023, up 298% quarter-over-quarter.
  • 6 funds opened new Lipocine positions in Q1 2023 and 10 closed out, a net change of -4 holders.
  • The largest Lipocine buyer in Q1 2023 was Millennium Management, an estimated $55.7K added.
  • The largest Lipocine seller in Q1 2023 was Wealth Effects, an estimated $192K sold.

Based on aggregated 13F filings for Q1 2023.